Eli Lilly
3,914 hedge funds and large institutions have $603B invested in Eli Lilly in 2024 Q4 according to their latest regulatory filings, with 510 funds opening new positions, 1,536 increasing their positions, 1,473 reducing their positions, and 197 closing their positions.
159% more first-time investments, than exits
New positions opened: 510 | Existing positions closed: 197
7% more funds holding
Funds holding: 3,664 → 3,914 (+250)
4% more repeat investments, than reductions
Existing positions increased: 1,536 | Existing positions reduced: 1,473
0.65% more ownership
Funds ownership: 81.62% → 82.27% (+0.65%)
9% less call options, than puts
Call options by funds: $9.28B | Put options by funds: $10.1B
12% less capital invested
Capital invested by funds: $687B → $603B (-$84.4B)
29% less funds holding in top 10
Funds holding in top 10: 473 → 337 (-136)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.67B |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$1.36B |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$1.24B |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$997M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$803M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.77B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.07B |
| 3 |
Jennison Associates
New York
|
-$1.78B |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.34B |
| 5 |
Primecap Management
Pasadena,
California
|
-$773M |
LLY Hedge Fund Activity: Q4 2024 in Review
3,914 of the 7,608 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q4 2024, worth a combined $603B — down 12% from $687B a quarter earlier.
Buyers outnumbered sellers: 510 funds opened new LLY positions and 197 closed out — a net gain of 313 holders — while 1,536 added to existing stakes and 1,473 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $1.67B. The largest seller was JP Morgan Chase, cutting an estimated $2.77B.
- 3,914 institutional investors held Eli Lilly (LLY) as of Q4 2024, up from 3,664 in Q3 2024.
- Funds reported $603B of Eli Lilly stock for Q4 2024, down 12% quarter-over-quarter.
- 510 funds opened new Eli Lilly positions in Q4 2024 and 197 closed out, a net change of +313 holders.
- The largest Eli Lilly buyer in Q4 2024 was Wellington Management Group, an estimated $1.67B added.
- The largest Eli Lilly seller in Q4 2024 was JP Morgan Chase, an estimated $2.77B sold.
Based on aggregated 13F filings for Q4 2024.